Key result
Primary angioplasty applies to ~85% of acute MI patients compared with under 50% for fibrinolysis.
Why the study?
The decision between balloon angioplasty and fibrinolytic infusion for reperfusion treatment in acute myocardial infarction remains controversial due to differences in applicability and availability of each treatment.
Does a strategy of emergency revascularisation improve outcomes compared to initial medical stabilisation in acute myocardial infarction?
Does a strategy of emergency revascularisation improve outcomes compared to initial medical stabilisation in acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
The SHOCK trial compared emergency revascularisation to initial medical stabilisation, not PTCA to lysis, though data were unpublished at the time of this text.
he decision over whether to treat acute myocardial infarction (AMI) with a balloon or infusion of fibrinolytics remains controversial.During the past few years profound changes in both treatment modalities 1-3 w1 w2 have substantially changed the arguments surrounding this longstanding debate.w3-5 The evidence shows that the alternative use of primary angioplasty or fibrinolysis is rarely an option, either because angioplasty is simply not available or because the patient is not eligible for fibrinolysis.This evidence reflects the difference in "applicability" of each treatment-that is, the proportion of patients in whom only one of the treatments would be suitable versus patients in whom either treatment would be appropriate.As a matter of fact, primary angioplasty is applicable to almost all victims of AMI (82-90% of patients randomised to primary angioplasty actually undergo the procedure), but it is not available to the majority of patients.Conversely, fibrinolysis is a widely available treatment but "applicable" to a variable percentage of patients which does not reach 50%.The large number of patients with AMI to whom fibrinolysis is not administered represents a big challenge for the future, and perhaps the most rational and undisputed argument in favour of the use of primary angioplasty.The best reperfusion treatment is one that achieves the highest rate of early, complete and sustained infarct related artery patency in the largest number of patients, but with the lowest rate of undesirable effects.The results obtained with both treatments, in the way they were applied before the latest breakthroughs in the field, can be represented by a geometrically opposing relation between "applicability" and "efficacy" (fig 1).
No takes yet. Share an insight, caveat, or question.
Flavio Ribichini (2002) conducted a review in Acute myocardial infarction. Primary angioplasty vs. Fibrinolysis was evaluated. Primary angioplasty is applicable to 82-90% of acute myocardial infarction patients, whereas fibrinolysis is applicable to less than 50%, reflecting a trade-off between applicability and efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: